A committee of the European Medicines Agency (EMA) has accepted for review GSK’s marketing authorization application for Blenrep (belantamab mafodotin) to be used as part of a combination treatment for people with relapsed or refractory multiple myeloma (RRMM). The Committee for Medicinal Products for Human Use (CHMP) will…
Through its Myeloma Investment Fund, the Multiple Myeloma Research Foundation (MMRF) has invested $1 million in novel CAR T-cell technology from Dynamic Cell Therapies (DCT) that aims to better treat multiple myeloma. Backed by this investment, DCT remains on track to move a new CAR T-cell…
The Leukemia & Lymphoma Society (LLS) is once again running its Scenic Shore Bike Tour to raise awareness and support for people with blood cancers, including myeloma. Going on its 32nd edition and set to start July 27 in Mequon, Wisconsin, the annual Scenic Shore Bike Tour…
Researchers in Germany have identified proteins that could help identify multiple myeloma patients who at high risk for an aggressive disease course and worse prognosis. Across a series of experiments, the scientists uncovered protein-level molecular changes that appeared specific to myeloma and correlated with disease progression patterns and myeloma…
Pfizer’s Elrexfio (elranatamab) extends the lives of adults with relapsed or refractory multiple myeloma (RRMM) who received at least two prior lines of therapy and whose cancer has worsened since their last treatment. Median overall survival was 24.6 months, or more than two years, according to data from the 123 RRMM…
A Phase 3 clinical trial evaluating the safety and efficacy of AbbVie’s experimental therapy ABBV-383 in adults with relapsed or refractory multiple myeloma (RRMM) has treated its first patient. Called CERVINO (NCT06158841), the study plans to enroll up to 380 patients, ages 18 and older, at…
A single infusion of the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) was sufficient to control disease activity in most multiple myeloma patients who hadn’t fully responded to a standard autologous stem cell transplant (ASCT). That’s according to new data from the 17 patients in cohort D of the…
GSK‘s Blenrep (belantamab mafodotin) cut the risk of cancer progression nearly in half compared with bortezomib when used in combination with other therapies to treat multiple myeloma patients who’d had at least one previous disease relapse. The benefits of Blenrep, used in combination with Pomalyst (pomalidomide) and…
The U.S. Food and Drug Administration (FDA) has granted priority review to Sanofi’s application of Sarclisa (isatuximab) in combination with standard of care for treating people newly diagnosed with multiple myeloma who aren’t eligible for a transplant. Priority review is given to therapies that target serious medical conditions…
Once-weekly induction therapy with bortezomib is as efficient as the standard two times a week dosing in people newly diagnosed with multiple myeloma, a large retrospective real-world study suggests. No differences were seen between both regimens regarding survival overall and the time patients lived without disease progression, but the…
Get regular updates to your inbox.